Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Headline
The Centers for Disease Control and Prevention Feb. 26 announced that an infant botulism outbreak that sickened 48 babies who consumed ByHeart formula is over…
Headline
The measles outbreak in South Carolina has increased to 876 cases, the state’s Department of Public Health reported Feb. 3. Last week, the South Carolina…
Headline
Thomas McGinn, M.D., senior executive vice president and chief physician executive officer at CommonSpirit Health, shares how the organization aligns…
Headline
The Centers for Disease Control and Prevention released its annual progress report on health care-associated infections Jan. 29, which found continued…
Headline
Two AHA guides offer strategies for hospitals and health systems in preparing for public health emergencies and disasters and managing cybersecurity incidents…
Headline
Stephanie Calcasola, R.N., chief quality officer and vice president of quality and safety at Hartford HealthCare, unpacks the programs, technology and cultural…